Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

121.70EUR
11:35am EDT
Change (% chg)

€-0.05 (-0.04%)
Prev Close
€121.75
Open
€120.80
Day's High
€122.00
Day's Low
€119.75
Volume
1,871,375
Avg. Vol
1,917,315
52-wk High
€123.90
52-wk Low
€86.03

Latest Key Developments (Source: Significant Developments)

Monsanto reports Q3 earnings per share $1.90
8:00am EDT 

June 28 (Reuters) - Monsanto Co :Monsanto Company delivers solid third quarter as it looks to close out fiscal year 2017 with return to growth.Q3 earnings per share $1.93 from continuing operations.Q3 earnings per share $1.90.Q3 sales $4.23 billion versus I/B/E/S view $4.17 billion.Q3 earnings per share view $1.76 -- Thomson Reuters I/B/E/S.Monsanto Co - Expects full-year 2017 EPS at high end of range of $4.09 to $4.55 on an as-reported basis.Monsanto Co - Confirms EPS at high end of range of $4.50 to $4.90 on an ongoing basis for full-year 2017.Monsanto Co - Qtrly total seeds and genomics sales $3,132 million versus $3,207 million.Monsanto Co - Co ‍simultaneously working with Bayer toward completion of pending merger by end of calendar year​.Monsanto Co - Seed and genomics segment gross profit is now expected to be up high-single digits in terms of percentage for year.Monsanto Co - For agricultural productivity segment, gross profit is still expected to be in range of $850 to $950 million for 2017.Says ‍looking ahead to Q4, "company expects to receive benefit of about $70 million in non-core asset sale gains from strategic deals​".Monsanto Co - For full year, company still expects earnings to translate to high end of range of $1.2 billion to $1.6 billion of free cash flow.Monsanto - ‍Remains on-track with target of $380 million in savings by end of FY across cost of goods and operating expenses, as compared to FY 2015 base​.  Full Article

Bayer's Stivarga approved for hepatocellular carcinoma in Japan
Monday, 26 Jun 2017 03:00am EDT 

June 26 (Reuters) - Bayer AG :Says receives approval for Stivarga in Japan for second-line treatment of hepatocellular carcinoma.  Full Article

Bayer gets positive CHMP opinion for regorafenib
Friday, 23 Jun 2017 08:34am EDT 

June 23 (Reuters) - BAYER AG ::‍BAYER RECEIVES POSITIVE CHMP OPINION FOR REGORAFENIB FOR SECOND-LINE SYSTEMIC TREATMENT OF LIVER CANCER​.‍FINAL DECISION OF EUROPEAN COMMISSION ON MARKETING AUTHORIZATION IS EXPECTED IN COMING MONTHS​.  Full Article

Bayer says receives FDA approval of myBETAapp and BETACONNECT navigator
Tuesday, 30 May 2017 11:37am EDT 

May 30 (Reuters) - Bayer :Bayer receives fda approval of mybetaapp™ and betaconnect navigator.Says bayer receives fda approval of mybetaapp™ and betaconnect navigator.  Full Article

Evotec receives milestone as part of alliance with Bayer
Monday, 22 May 2017 01:29am EDT 

May 22 (Reuters) - Evotec AG :Evotec receives pre-clinical milestone as part of its endometriosis alliance with Bayer.Payment of approx. Eur 5 m to Evotec for transition of a programme into pre-clinical development for treatment of endometriosis.This milestone was achieved under successful strategic alliance between Evotec and Bayer entered in october 2012.  Full Article

FDA grants Bayer priority review for investigational compound Copanlisib
Wednesday, 17 May 2017 02:30am EDT 

May 17 (Reuters) - Bayer Ag :FDA grants Bayer priority review for investigational compound Copanlisib in Follicular Lymphoma.U.S. Food and drug administration has granted priority review designation for new drug application for Copanlisib.  Full Article

FDA grants priority review to Bayer anti-cancer compound
Wednesday, 17 May 2017 02:00am EDT 

May 17 (Reuters) - Bayer AG :Says receives FDA priority review for investigational anti-cancer compound copanlisib.  Full Article

Bayer still sees competition after Monsanto takeover
Friday, 28 Apr 2017 10:15am EDT 

April 28 (Reuters) - Bayer AG CEO at AGM:Says assumes that there will still be considerable competition even after Monsanto <<>> deal is completed.  Full Article

Monsanto deal hasn't affected Bayer business - Bayer CEO
Friday, 28 Apr 2017 09:21am EDT 

April 28 (Reuters) - Bayer AG CEO at AGM:Says Monsanto takeover has so far not had any visible effect on the development of our business.  Full Article

U.S. FDA expands approved use of Stivarga to treat liver cancer
Thursday, 27 Apr 2017 12:54pm EDT 

April 27 (Reuters) - U.S. FDA::FDA expands approved use of Stivarga to treat liver cancer.The FDA granted the approval of Stivarga to Bayer Healthcare Pharmaceuticals Inc.  Full Article

More From Around the Web

Photo

Monsanto profit tops expectations as soybean sales surge

U.S. seeds and agrochemicals company Monsanto Co , which is in the process of being bought by Germany's Bayer AG , reported a stronger-than-expected quarterly profit on Wednesday as record soybean plantings lifted seed sales. | Video